Opthea’s flagship clinical trial has failed, with the biotech’s solvency now on the line
Biotechnology firm Opthea has warned investors its solvency is in question after the failure of a major clinical trial into ...
Investors fret over clinical trial failure’s hit on Regal funds
Phil King’s investment firm was the largest shareholder in Opthea, the eye treatment play who warned it could be insolvent ...
Opthea’s survival in doubt after late-stage eye drug trial fails
Opthea (ASX:OPT) has announced that its lead drug candidate sozinibercept has failed to meet primary endpoints in a phase 3 ...
Opthea Announces COAST Phase 3 Trial Topline Results
COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52Opthea considering impact of negative trial ...
HotCopper on MSN5h
Opthea's Phase 3 trial results fail to help patients, future of company at risk
It mightn’t be too surprising Opthea (ASX:OPT) applied for a voluntary suspension last week ahead of Monday’s Phase 3 trial ...
Stockhead on MSN6h
Health Check: Opthea’s solvency in question after monumental phase III eye disease trial failure
One of two of Opthea's phase III trials for a common eye disease has failed to meet its objectives, casting doubts on the ...
Regal on watch over $200m biotech failure risk, shares dive
Investors have wiped more than $100m from the value of Regal Funds on Monday, with fears that a position in one of its stocks ...
Capital Brief4h
Regal Partners shares tank as Opthea warns of funding concerns
Shares in Regal Partners tumbled after its 30%-owned biotech Opthea said there was "material uncertainty" of its "ability to ...
Trading in Opthea Halted Ahead of Update on Wet AMD Study
Trading in shares of Opthea is halted in the U.S. and Australia ahead of planned update by the clinical-stage biopharmaceutical company on a late-stage study of its lead product candidate ...
HotCopper on MSN5h
Monday’s HotCopper Trends: Opthea strife, Memphasys best-in-class results | March 21, 2025
The ASX has been trading flat at around 7,928 points. Discretionary has been the best-performing sector today, up 1%, ...
It’s Phil King’s Regal against the shorts at biotech play Opthea
The high-profile stockpicker is the eye disorder treatment hopeful’s biggest shareholder. Ahead of the results of a crucial ...
Opthea Ltd (ADR) trading halted, news pending
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...